Swiss National Bank Acquires 300 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Swiss National Bank boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 0.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 51,800 shares of the company’s stock after acquiring an additional 300 shares during the period. Swiss National Bank owned 0.17% of Medpace worth $17,210,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. State Street Corp increased its position in Medpace by 7.2% during the 3rd quarter. State Street Corp now owns 752,957 shares of the company’s stock worth $251,337,000 after buying an additional 50,312 shares during the period. Geode Capital Management LLC increased its position in Medpace by 7.6% during the 3rd quarter. Geode Capital Management LLC now owns 628,054 shares of the company’s stock worth $209,885,000 after buying an additional 44,371 shares during the period. Wellington Management Group LLP increased its position in Medpace by 36.0% during the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after buying an additional 109,886 shares during the period. American Capital Management Inc. increased its position in Medpace by 2.6% during the 3rd quarter. American Capital Management Inc. now owns 380,646 shares of the company’s stock worth $127,060,000 after buying an additional 9,592 shares during the period. Finally, GW&K Investment Management LLC increased its position in Medpace by 93.9% during the 4th quarter. GW&K Investment Management LLC now owns 275,460 shares of the company’s stock worth $91,516,000 after buying an additional 133,379 shares during the period. Institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

Separately, Robert W. Baird increased their price objective on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Medpace currently has a consensus rating of “Hold” and a consensus target price of $381.44.

Medpace Stock Performance

MEDP opened at $322.93 on Wednesday. The firm has a market cap of $9.84 billion, a P/E ratio of 25.57, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 52-week low of $302.01 and a 52-week high of $459.77. The business’s fifty day moving average is $339.49 and its 200-day moving average is $340.34.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.